Clinical trials: MGD-Meibomian Gland Dysfunction
- Condition MGD-Meibomian Gland Dysfunction
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Meibomian Gland Dysfunction
A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction
This study will evaluate the safety and efficacy of AGN-195263 compared to vehicle in patients with meibomian gland dysfunction (MGD) in the eyelids.
- Trial name
- NCT01633788
- Testing
- AGN-195263 0.1%, AGN-195263 0.03%, AGN-195263 0.01%
- Where
- 33 sites in United States
- Volunteers
- 232 people
- Sponsor
- Allergan
Meibomian Gland Dysfunction
Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)
AZ202001 is a multicenter study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD)
- Trial name
- NCT04391959
- Testing
- AZR-MD-001 Active, AZR-MD-001 Vehicle
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 31 people
- Sponsor
- Azura Ophthalmics
Dry Eye, Meibomian Gland Dysfunction
Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)
To demonstrate the safety and effectiveness of TearCare® procedures compared to Restasis® to treat the signs and symptoms of dry eye disease in adult patients.
- Trial name
- NCT04795752
- Testing
- TearCare System, Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion
- Where
- 14 sites in United States
- Volunteers
- 345 people
- Sponsor
- Sight Sciences, Inc.
Dry Eye Syndromes, Dry Eye
Evaluate the Safety and Effectiveness of The Tixel Fractional System in the Treatment of Meibomian Gland Disfunction
A Randomized, Masked (Evaluator), Controlled, Prospective Pilot Study of the Effectiveness and Safety of the Tixel®, Versus LipiFlow® in the Treatment of Meibomian Gland Dysfunction.
- Conditions
- Dry Eye Syndromes, Dry Eye, Meibomian Gland Dysfunction
- Trial name
- NCT04889950
- Testing
- Tixel C, LipiFlow
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Novoxel Ltd.
Dry Eye Disease (DED)
Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)
This trial will evaluate the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland…
- Trial name
- NCT04139798
- Testing
- NOV03
- Where
- 29 sites in United States
- Volunteers
- 599 people
- Sponsor
- Bausch & Lomb Incorporated
Meibomian Gland Dysfunction, Dry Eye
Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers
The pilot study objective is to evaluate the potential benefits of LipiFlow® System treatment of contact lens wearers with meibomian gland dysfunction and evaporative dry eye by assessing for improvement in meibomian gland…
- Trial name
- NCT02102464
- Testing
- LipiFlow treatment
- Where
- 6 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- TearScience, Inc.
Blepharitis, Dry Eye Syndrome
Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery
The purpose of this pilot feasibility study is to assess whether treating meibomian gland dysfunction (MGD) prior to cataract surgery helps promote meibomian gland function, visual quality and ocular comfort after cataract…
- Trial name
- NCT01808560
- Testing
- LipiFlow Pre-Treatment, LipiFlow Post-treatment
- Where
- 7 sites in United States
- Volunteers
- 34 people
- Sponsor
- TearScience, Inc.
Dry Eye, Meibomian Gland Dysfunction
TearCare System to Treat Dry Eye Disease
In this study, the TearCare System will be compared with the LipiFlow Thermal Pulsation System in patients with dry eye disease.
- Trial name
- OLYMPIA (NCT03857919)
- Testing
- TearCare, LipiFlow
- Where
- 10 sites in United States
- Volunteers
- 235 people
- Sponsor
- Sight Sciences, Inc.
Dry Eye Syndrome
Effectiveness of Intense Pulsed Light for Improving Dry Eye Syndrome
The aim of the current study is to examine the contribution of intense pulsed light (IPL) for relieving signs and symptoms of dry eye due to meibomian gland dysfunction.
- Trial name
- NCT03396913
- Testing
- IPL, MGX
- Where
- 2 sites in United States
- Volunteers
- 88 people
- Sponsor
- Lumenis Be Ltd.
Evaporative Dry Eye
iLux Treatment for Meibomian Gland Dysfunction (MGD)
The purpose of this study is to assess changes in meibomian gland function and evaporative dry eye symptoms after treatment with the iLux medical device.
- Trial name
- NCT03055650
- Testing
- iLux 2020 System
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tear Film Innovations, Inc.
Chalazion, Dry Eye Syndromes
Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction
The objective is to evaluate the feasibility of using additional screening methods to optimize effectiveness outcomes with the LipiFlow System for application of heat and pressure therapy in adult patients with chronic cystic…
- Trial name
- NCT01202747
- Testing
- LipiFlow System
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- TearScience, Inc.
Meibomian Gland Dysfunction
Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction
The objective of this study is to assess the safety and efficacy of testosterone 0.03% ophthalmic solution compared to vehicle for the treatment of meibomian gland dysfunction.
- Trial name
- NCT00755183
- Testing
- testosterone ophthalmic solution, vehicle of testosterone ophthalmic solution
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- ORA, Inc.
Blepharitis
Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 ophthalmic suspension compared to vehicle (placebo) in subjects with signs and symptoms of inflammatory meibomian gland disease.
- Trial name
- Maui (NCT02218489)
- Testing
- KPI-121, Vehicle
- Where
- 8 sites in United States
- Volunteers
- 206 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Meibomian Gland Dysfunction
Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD)
Single-center, single-masked (the individual(s) performing efficacy and safety measures will be masked to treatment assignment for the patient(s) they are assessing), vehicle-controlled, randomized study.
- Trial name
- NCT04314362
- Testing
- AZR-MD-001 ointment/semi-solid drug
- Where
- Australia
- Volunteers
- 32 people
- Sponsor
- Azura Ophthalmics
Meibomian Gland Dysfunction, Dry Eye Syndromes
to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction
A Randomized, Masked (Evaluator), Controlled, Prospective Study Evaluating the Effectiveness and Safety of the Tixel® Medical Device, Versus LipiFlow® in the Treatment of Meibomian Gland Dysfunction
- Conditions
- Meibomian Gland Dysfunction, Dry Eye Syndromes, Dry Eye
- Trial name
- NCT05162261
- Testing
- Tixel C, LipiFlow
- Where
- 5 sites in United States
- Volunteers
- 109 people
- Sponsor
- Novoxel Ltd.
Meibomian Gland Dysfunction
Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction
The purpose of this study was to compare changes in meibomian gland dysfunction (MGD), tear break-up time (TBT) and evaporative dry eye (EDE) symptoms after treatment with either the iLux® 2020 System or the LipiFlow® Thermal…
- Trial name
- NCT03055832
- Testing
- iLux 2020 System, LipiFlow Pulsation System
- Where
- 7 sites in United States
- Volunteers
- 142 people
- Sponsor
- Tear Film Innovations, Inc.
Meibomian Gland Dysfunction (MGD), Contact Lens Discomfort (CLD)
An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)
SOVS2019-070 is a single-center study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD).
- Trial name
- NCT03972501
- Testing
- AZR-MD-001 Vehicle, AZR-MD-001 Active Dose
- Where
- Australia
- Volunteers
- 26 people
- Sponsor
- Azura Ophthalmics
Cataracts, Meibomian Gland Dysfunction (MGD)
A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice
This is a post-market, prospective, randomized, multi-center, bilateral, open-label, cross-over, comparative clinical study. Study group will undergo preoperative LipiFlow treatment and Control group will not receive preoperative…
- Trial name
- NCT03708367
- Testing
- LipiFlow Thermal Pulsation System
- Where
- 5 sites in United States
- Volunteers
- 117 people
- Sponsor
- Johnson & Johnson Surgical Vision, Inc.
Dry Eye Disease
Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)
The objectives of this trial are to assess the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with…
- Trial name
- NCT04567329
- Testing
- NOV03, Saline Solution
- Where
- 35 sites in United States
- Volunteers
- 620 people
- Sponsor
- Bausch & Lomb Incorporated
Posterior Blepharitis, Meibomian Gland Dysfunction
Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction
This study will evaluate the safety, tolerability and efficacy of AXR-270 Cream in treating posterior blepharitis associated with Meibomian Gland Disease (MGD)
- Trial name
- NCT04469998
- Testing
- AXR-270 Low Dose, AXR-270 High Dose, AXR-270 Vehicle
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- AxeroVision, Inc.